Caris Life Sciences vs Proscia Concentriq
A biopharma team running a companion-diagnostic program might use both names, for different jobs. Proscia's life sciences line covers biomarker research, trials and companion diagnostics on pathology images, and Concentriq also serves clinical case review. Agilent announced on October 13, 2026 an agreement to buy Proscia for up to $270M, with $240M in cash at closing plus up to $30M of earnout, expected to close early in Agilent's fiscal 2027. Proscia announced SOC 2 Type II in December 2025.
Caris supplies the sequencing side. MI Cancer Seek lists companion-diagnostic indications for PIK3CA with Piqray, KRAS/NRAS wild-type with Vectibix, and MSI-H with Keytruda and Jemperli, at a median turnaround of 8 days. A clinical lab that wants digital case review buys Proscia, and an oncologist who needs a companion-diagnostic result orders from Caris.
Pathology · Reviewed November 2, 2026
Caris Life Sciences
by Caris Life Sciences · founded 2008
FDA-approved MI Cancer Seek tumor profiling test for oncologists. The GPSai tissue-of-origin AI is a lab service outside that approval.
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
When to pick each one
Caris Life Sciences
- Companion-diagnostic claims for Piqray, Vectibix and Keytruda
- Median turnaround of 8 days
Proscia Concentriq
- SOC 2 Type II announced December 2025
- Life sciences line plus clinical case review
- Agilent purchase pending, up to $270M
Score
Each row shows points earned of points available under the published rubric.
Caris Life Sciences
65of 100
Proscia Concentriq
40of 100
| Dimension | Caris Life Sciences | Proscia Concentriq | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 6 / 10 | -6 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 21 / 21 | 0 / 21 | +21 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Caris Life Sciences
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Proscia Concentriq
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Demo request only. |
Evidence
Caris Life Sciences
FDA decisions
P240010 (opens in new tab)PMA2024-11-05
MI Cancer Seek
Peer-reviewed
5 PubMed records name Caris Life Sciences.
- An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins. (opens in new tab)
- Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program. (opens in new tab)
- ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers. (opens in new tab)
Proscia Concentriq
FDA decisions
K261380 (opens in new tab)510(k)2026-08-05
Concentriq AP-Dx
K230839 (opens in new tab)510(k)2024-02-08
Concentriq Dx (marketed as Concentriq AP-Dx)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Caris Life Sciences | Proscia Concentriq |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2008 | n/a |
| HQ | US | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.